Alector, Inc. (ALEC)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
1.49 USD
+0.10
(6.835%)
⇧
(July 15, 2026, 11:21 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:18 a.m. EDT
The investment case for Alector has collapsed. The company is facing a catastrophic multi-year decline, having lost over 91% of its value since 2019, with four consecutive years of negative annual returns culminating in a massive 70% drop last year. This structural deterioration was accelerated by the termination of its major partnership with GSK, which forced a painful pipeline reset and repayment of significant debt. Fundamentally, the business is deteriorating rapidly with shrinking revenues (-71%), negative operating margins, and severe cash burn that has depleted reserves to just $206 million against $34.5 million in debt, leaving little runway without further capital raises. While the stock recently rallied on a technical bounce, the underlying fundamentals remain broken. There is no dividend to provide income, and the options market reflects deep pessimism with heavy put positioning. At this stage, the risk of permanent capital loss outweighs any speculative recovery potential. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.264493 |
| AutoARIMA | 0.265531 |
| AutoETS | 0.265536 |
| AutoTheta | 0.333472 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 6.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.169 |
| Excess Kurtosis | -1.11 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 332.768 |
| Revenue per Share | 0.174 |
| Market Cap | 164,872,400 |
| Forward P/E | -2.12 |
| Beta | 0.60 |
| Website | https://www.alector.com |
As of July 11, 2026, 6:18 a.m. EDT: Speculators are overwhelmingly bearish, with massive put volume and open interest concentrated at strikes below the current price (1.0 and 1.5), while call activity is negligible and focused on distant out-of-the-money strikes. Implied volatility is extremely low, suggesting a lack of speculative optimism despite the recent price dip.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.10897434 |
| Address1 | 131 Oyster Point Boulevard |
| Address2 | Suite 600 |
| All Time High | 43.32 |
| All Time Low | 0.87 |
| Ask | 1.81 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 2.6 - Hold |
| Average Daily Volume10 Day | 551,120 |
| Average Daily Volume3 Month | 722,057 |
| Average Volume | 722,057 |
| Average Volume10Days | 551,120 |
| Beta | 0.599 |
| Bid | 1.08 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 0.094 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.485 |
| Current Ratio | 5.25 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.525 |
| Day Low | 1.37 |
| Debt To Equity | 332.768 |
| Display Name | Alector |
| Earnings Call Timestamp End | 1,754,598,600 |
| Earnings Call Timestamp Start | 1,754,598,600 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -127,494,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.138 |
| Enterprise To Revenue | -0.958 |
| Enterprise Value | -17,641,990 |
| Eps Current Year | -0.88333 |
| Eps Forward | -0.7 |
| Eps Trailing Twelve Months | -1.19 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.9485 |
| Fifty Day Average Change | -0.46350002 |
| Fifty Day Average Change Percent | -0.2378753 |
| Fifty Two Week Change Percent | -10.897434 |
| Fifty Two Week High | 3.4 |
| Fifty Two Week High Change | -1.9150001 |
| Fifty Two Week High Change Percent | -0.5632353 |
| Fifty Two Week Low | 1.09 |
| Fifty Two Week Low Change | 0.39499998 |
| Fifty Two Week Low Change Percent | 0.3623853 |
| Fifty Two Week Range | 1.09 - 3.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,549,549,800,000 |
| Float Shares | 83,800,701 |
| Forward Eps | -0.7 |
| Forward P E | -2.1214287 |
| Free Cashflow | -119,106,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 103 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -88,864,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09669 |
| Held Percent Institutions | 0.82196 |
| Implied Shares Outstanding | 111,025,187 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California. |
| Long Name | Alector, Inc. |
| Market | us_market |
| Market Cap | 164,872,400 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_249249899 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -125,388,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 154,325,009 |
| Number Of Analyst Opinions | 5 |
| Open | 1.39 |
| Operating Cashflow | -173,060,992 |
| Operating Margins | -23.82314 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 415 231 5660 |
| Previous Close | 1.39 |
| Price Eps Current Year | -1.6811385 |
| Price Hint | 4 |
| Price To Book | 15.7978735 |
| Price To Sales Trailing12 Months | 8.952186 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.041 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.57143 |
| Region | US |
| Regular Market Change | 0.09500003 |
| Regular Market Change Percent | 6.8345346 |
| Regular Market Day High | 1.525 |
| Regular Market Day Low | 1.37 |
| Regular Market Day Range | 1.37 - 1.525 |
| Regular Market Open | 1.39 |
| Regular Market Previous Close | 1.39 |
| Regular Market Price | 1.485 |
| Regular Market Time | 1,784,128,861 |
| Regular Market Volume | 321,740 |
| Return On Assets | -0.25707 |
| Return On Equity | -2.38852 |
| Revenue Growth | -0.715 |
| Revenue Per Share | 0.174 |
| Sand P52 Week Change | 0.2043345 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 111,025,187 |
| Shares Percent Shares Out | 0.0515 |
| Shares Short | 5,716,527 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,085,727 |
| Short Name | Alector, Inc. |
| Short Percent Of Float | 0.0545 |
| Short Ratio | 5.79 |
| Source Interval | 15 |
| State | CA |
| Symbol | ALEC |
| Target High Price | 6.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 3.1 |
| Target Median Price | 2.0 |
| Total Cash | 206,515,008 |
| Total Cash Per Share | 1.86 |
| Total Debt | 34,548,000 |
| Total Revenue | 18,417,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.19 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.9842 |
| Two Hundred Day Average Change | -0.4992 |
| Two Hundred Day Average Change Percent | -0.25158754 |
| Type Disp | Equity |
| Volume | 321,740 |
| Website | https://www.alector.com |
| Zip | 94,080 |